Bristol-Myers Squibb (BMY) Revenue — Quarter Ended Sep 30, 2023
Revenue declined relative to both the prior quarter and the same period one year earlier. The downward trajectory continued a pattern seen across the most recent four quarters.
Key takeaway
Quarter ended Sep 30, 2023 · FY2023 Q3
Revenue declined relative to both the prior quarter and the same period one year earlier. The downward trajectory continued a pattern seen across the most recent four quarters.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$11B
Revenue reported for this quarter.
Quarter-over-quarter
-2.3%
Change from the immediately preceding quarter.
Year-over-year
-2.2%
Change from the comparable year-ago quarter.
Trailing four quarters
$44.9B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $11.4B | -4.8% |
| Mar 31, 2023 | $11.3B | -2.7% |
| Jun 30, 2023 | $11.2B | -5.6% |
| Sep 30, 2023 | $11B | -2.2% |
Revenue performance
The reported revenue fell compared with the immediately preceding quarter. The decline also matched the year-over-year decrease from one year ago.
Quarterly comparison
The sequential decline from the prior quarter was modest, and the year-over-year drop was nearly identical. This quarter’s revenue continued the shrinking sequence observed in each preceding period of the fiscal year.
What to watch
Revenue has contracted for four consecutive quarters, with the rate of decline narrowing in the latest period.